Armodafinil

證據等級: L5

預測適應症: 1 個

Armodafinil: From Narcolepsy to Insomnia

One-Sentence Summary

Armodafinil is the R-enantiomer of modafinil, approved in the United States as a wakefulness-promoting agent for excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work disorder (SWD). The TxGNN model predicts it may be effective for Insomnia, with 12 clinical trials and 19 publications currently touching this direction — though the mechanistic connection is indirect and potentially paradoxical, as the drug’s core action promotes wakefulness rather than sleep.

Quick Overview

Item	Content
Original Indication	Excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder
Predicted New Indication	Insomnia (disease)
TxGNN Prediction Score	99.89%
Evidence Level	L3
US Market Status	Not found in database (0 records returned)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on well-established pharmacology, Armodafinil is the R-enantiomer of modafinil — a wakefulness-promoting agent that primarily works through dopamine transporter (DAT) inhibition, increasing dopaminergic tone in arousal-related brain circuits (hypothalamic histamine pathways, noradrenergic locus coeruleus). Its core pharmacological effect is to sustain alertness and reduce excessive daytime sleepiness, not to facilitate sleep onset or sleep continuity.

The mechanistic connection to insomnia is, at best, counterintuitive. Insomnia treatment generally requires promoting sleep initiation or maintenance, whereas armodafinil acts in the opposite direction. The clinical trials captured in this evidence pack link armodafinil to “insomnia” through three indirect pathways: (1) oncology patients simultaneously experiencing insomnia and cancer-related fatigue, where armodafinil targets fatigue while CBT-I addresses insomnia; (2) sleep-disordered breathing (OSA/SDB) comorbid with insomnia, where armodafinil treats residual daytime sleepiness rather than insomnia itself; and (3) Phase 3 trials for the drug’s approved indications (narcolepsy, OSA), where insomnia appears as a safety monitoring variable, not a treatment outcome.

One narrow scenario where armodafinil might theoretically help: patients with circadian rhythm disruption (e.g., shift work disorder) who experience insomnia as a component of schedule misalignment — but this represents a highly specific subgroup, and even then, the primary effect would be on alertness during work hours, not sleep quality during off-hours. The TxGNN model’s high score (99.89%) most likely reflects co-occurrence of insomnia-related terminology across the knowledge graph rather than a validated therapeutic relationship. Prescribing armodafinil for primary insomnia without further mechanistic evidence carries a meaningful risk of worsening the condition.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01019187	Phase 2	Completed	226	CBT with or without armodafinil for insomnia and fatigue in cancer survivors post-chemotherapy; armodafinil primarily targets fatigue, CBT-I targets insomnia
NCT01011218	Phase 2	Completed	70	Pilot RCT of brief behavioral therapy (BBT-I or CBT-I) ± armodafinil 150 mg/day for insomnia management in breast cancer patients
NCT01091974	Phase 2	Completed	138	Four-arm RCT of CBT-I ± armodafinil in breast cancer patients with sleep disturbances after chemotherapy completion
NCT02552303	Phase NA	Completed	39	Armodafinil and/or CBT-I for insomnia comorbid with sleep-disordered breathing; armodafinil role is treating OSA residual sleepiness, not insomnia
NCT01080807	Phase 4	Completed	385	Armodafinil 150 mg for excessive sleepiness in shift work disorder; insomnia is a co-morbidity of SWD, not the primary endpoint
NCT01072630	Phase 3	Completed	492	Adjunctive armodafinil (150 and 200 mg/day) vs placebo for major depression in Bipolar I disorder; sleep assessed as secondary outcome
NCT01072929	Phase 3	Completed	433	Fixed-dose adjunctive armodafinil for Bipolar I major depression; parallel-group DB/PC design
NCT01305408	Phase 3	Completed	399	Adjunctive armodafinil 150 mg/day for Bipolar I major depressive episodes alongside mood stabilizers
NCT00481195	Phase 2	Completed	257	8-week fixed-dose armodafinil 150 mg as adjunctive therapy for Bipolar I major depressive episodes
NCT00772005	Phase 2	Completed	287	24-week DB/PC armodafinil adjunctive therapy for negative symptoms of schizophrenia

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27010071	2016	Systematic Review	Parkinsonism & Related Disorders	Meta-analysis of pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson’s disease; modafinil/armodafinil class evaluated
22021174	2011	EBM Review	Movement Disorders	MDS Task Force evidence-based review of non-motor symptom treatments in PD including sleep disorders; wakefulness agents assessed
18729534	2008	Evidence-Based Review	Drugs	Comprehensive review of approved and off-label uses of modafinil (parent compound); covers narcolepsy, OSA, SWD, fatigue, and cognitive applications
24312590	2013	Systematic Review & Meta-analysis	PloS One	Modafinil efficacy for fatigue and excessive daytime sleepiness in neurological disorders; confirms class-wide wakefulness effect, not sleep-promoting
39535843	2024	Narrative Review	Expert Opinion on Pharmacotherapy	Pharmacological and non-pharmacological management of sleep disturbances in Parkinson’s disease; wakefulness agents reviewed in context of broader sleep dysfunction
24272458	2014	Review	Neurotherapeutics	Treatment of sleep disorders in Parkinson’s disease including insomnia, REM sleep behavior disorder; role of wakefulness-promoting agents discussed
21904092	2011	Review	Postgraduate Medicine	Shift work disorder pathophysiology and management; armodafinil cited for SWD-related excessive sleepiness; insomnia as component of SWD
17181377	2006	Review	Drugs	Shift work sleep disorder — burden of illness and management; wake-promoting agents’ role in reducing sleepiness during shifts, not treating sleep-onset insomnia
18805301	2008	Review	Revue Neurologique	Narcolepsy with cataplexy; sleep maintenance insomnia noted as an associated narcolepsy symptom; armodafinil class used for EDS, not the insomnia component
20166851	2010	Review	Expert Opinion on Emerging Drugs	Emerging treatments for narcolepsy and related disorders; armodafinil reviewed alongside novel wake-promoting agents

US Market Information

No FDA authorization records were returned from the regulatory database for Armodafinil.

⚠ Data Note: Armodafinil (brand name Nuvigil, Teva Pharmaceuticals) received FDA approval in June 2007 for narcolepsy, OSA-related excessive sleepiness, and shift work disorder. The database returning 0 records indicates a data gap in the current query system. Manual verification of the full FDA label — including approved indications, boxed warnings, and contraindications — is required before any clinical or regulatory decision-making.

Safety Considerations

Please refer to the package insert for safety information.

Data Gap: The regulatory database query returned no warnings, contraindications, or drug interaction records for Armodafinil. Given that armodafinil is a Schedule IV controlled substance in the United States, obtaining the complete FDA-approved prescribing information is a blocking prerequisite (DG001) before safety review can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: Armodafinil’s core pharmacological action — promoting wakefulness via dopamine reuptake inhibition — is directionally opposite to what insomnia treatment requires. All clinical trial evidence linking armodafinil to insomnia is indirect (cancer-related fatigue management, OSA co-morbidity, or approved-indication safety monitoring), and no trial has evaluated it as a primary treatment for primary insomnia in the general population. Proceeding without resolving the mechanistic paradox and the regulatory data gaps would be premature.

To proceed, the following is needed:

Obtain and parse the FDA-approved full prescribing information (Nuvigil label) — required to complete safety review (DG001, Blocking)
Retrieve complete mechanism of action data from DrugBank (DB06413) to determine whether any downstream effects (e.g., circadian entrainment, rebound sleep) could offer mechanistic rationale (DG002, High)
Define a specific target patient subgroup where a wakefulness-promoting effect could paradoxically benefit sleep (e.g., hypersomnia-insomnia phenotype in circadian rhythm disorder, or cancer-related fatigue-insomnia overlap)
Commission a dedicated literature search for armodafinil specifically in primary insomnia populations, separate from comorbid fatigue or SDB contexts
Assess risk of insomnia worsening as a primary safety concern if repurposing is pursued
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.